Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions
This article was originally published in The Pink Sheet Daily
In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.
You may also be interested in...
Regeneron's Inmazeb Overcame FDA Combo Product Requirements With Nonclinical Evidence
The individual contribution of the three mABs in Regeneron’s Ebola treatment could not be clinically tested due to the highly lethal nature of the disease and the potential for development of resistance; instead, the FDA accepted nonclinical data demonstrating the mechanism of action for each component.
ASCO's Richard Schilsky On State-of-the-Art Oncology Trials
ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.
Rethinking Oncology Development: Master Protocols May Shorten Time To Approval
Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”